PEPGPepGen Inc.Healthcare · Biotechnologyas of 2026-09-25
Horizon

Issued 2026-09-25 at $2.59 · now $2.59 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, PEPG has typically landed between $1.39 and $4.23 — a range of −46.3% to +63.3% from the issuance price $2.59.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,077 overlapping 1 month windows · 2022-05-06 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($2.59) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where PEPG has typically landed a month from the 2026-09-25 close of $2.59 — the range is history, not a prediction.

$1.39worst · -46.3%$4.23best · +63.3%
  • now $2.59 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.57 (-0.6%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.12–$3.02
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.39–$4.23
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,077 windows spanning 2022-05-06 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2026-03-04−74.4%−74.4%+0.0%
2026-03-11−73.9%−74.4%+0.0%
2026-03-10−73.9%−73.9%+2.1%
3 best
2025-09-03+331.1%+0.0%+331.1%
2025-09-02+323.3%−0.8%+323.3%
2025-08-29+306.0%+0.0%+337.1%

1,077 overlapping windows · 2022-05-06 – 2026-09-25 · not cherry-picked

Pending catalysts

  • March 2027 — Trial primary completion: Phase 2 primary completion: A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (source, as of 2026-08-14)
  • January 2029 — Trial primary completion: Phase 2 primary completion: An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~5 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
50%
−5.7%
n=4
Feb
75%
+58.0%
n=4
Mar
0%
−40.0%
n=4
Apr
50%
+2.7%
n=4
May
25%
+4.2%
n=4
Jun
20%
−11.6%
n=5
Jul
40%
−5.5%
n=5
Aug
40%
+5.8%
n=5
Sep
20%
+50.0%
n=5
Oct
75%
+3.6%
n=4
Nov
50%
+8.0%
n=4
Dec
50%
+1.1%
n=4

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$7$12026-05-21: 1 insider sale, $2K — Kasraian Kasra2026-03-04: 6 insider sales, $58K — McArthur James G, Donnelly Noel, STRECK PAUL …2025-09-30: 1 insider purchase, $640K — Oxford Science Enterprises plc2025-09-26: 1 insider purchase, $30.0M — RA CAPITAL MANAGEMENT, L.P.2025-09: 2 open-market purchases, $30.6M2026-03: 6 open-market sales, $58K2026-05: 1 open-market sale, $2K↑ buys↓ salesofficer Kasraian Kasra — Sale on 2026-05-21, filed 5 days after the tradedirector McArthur James G — Sale on 2026-03-04, filed 2 days after the tradeofficer Donnelly Noel — Sale on 2026-03-04, filed 2 days after the tradeofficer STRECK PAUL — Sale on 2026-03-04, filed 2 days after the tradedirector McArthur James G — Sale on 2026-03-04, filed 2 days after the tradeofficer Donnelly Noel — Sale on 2026-03-04, filed 2 days after the tradeofficer STRECK PAUL — Sale on 2026-03-04, filed 2 days after the tradeother Oxford Science Enterprises plc — Purchase on 2025-09-30, filed 1 day after the tradedirector RA CAPITAL MANAGEMENT, L.P. — Purchase on 2025-09-26, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-05-21Kasraian KasraofficerSale1,233 @ $1.41$2K−2.4% of holding+19.2%not yet — horizon still open50,074Form 4 · filed 5 days after the trade
2026-03-04McArthur James GdirectorSale5,144 @ $6.23$32K−1.7% of holding−70.4%−65.2%296,457Form 4 · filed 2 days after the trade
2026-03-04Donnelly NoelofficerSale2,032 @ $6.23$13K−1.8% of holding−70.4%−65.2%111,655Form 4 · filed 2 days after the trade
2026-03-04STRECK PAULofficerSale1,832 @ $6.23$11K−2.3% of holding−70.4%−65.2%76,273Form 4 · filed 2 days after the trade
2026-03-04McArthur James GdirectorSale131 @ $6.33$829−0.0% of holding−70.4%−65.2%296,326Form 4 · filed 2 days after the trade
2026-03-04Donnelly NoelofficerSale52 @ $6.33$329−0.0% of holding−70.4%−65.2%111,603Form 4 · filed 2 days after the trade
2026-03-04STRECK PAULofficerSale47 @ $6.29$296−0.1% of holding−70.4%−65.2%76,226Form 4 · filed 2 days after the trade
2025-09-30Oxford Science Enterprises plcotherPurchase200,000 @ $3.20$640K+4.2% of holding−5.6%−61.3%4,955,388Form 4 · filed 1 day after the trade
2025-09-26RA CAPITAL MANAGEMENT, L.P.directorPurchase9,375,000 @ $3.20$30.0M+102.1% of holding+3.6%−12.6%18,554,273Form 4 · filed 4 days after the trade
2025-05-30STRECK PAULofficerPurchase8,375 @ $1.24$10K+43.1% of holding−30.4%+280.5%27,805Form 4 · filed 3 days after the trade
2025-04-17McArthur James GdirectorPurchase10,000 @ $1.35$14K+9.6% of holding−1.0%+243.9%113,913Form 4 · filed 5 days after the trade
2025-04-08McArthur James GdirectorPurchase41,500 @ $1.15$48K+66.5% of holding+40.2%+367.0%103,913Form 4 · filed 1 day after the trade
2025-02-26Donnelly NoelofficerSale1,527 @ $1.68$3K−47.7% of holding+9.6%−28.4%1,673Form 4 · filed same day
2025-02-26DeLena Mary BethofficerSale1,432 @ $1.68$2K−47.7% of holding+9.6%−28.4%1,568Form 4 · filed same day
2024-07-25Mellion Michelle LofficerSale7,571 @ $18.06$137K−100.0% of holding−50.7%−101.7%0Form 4 · filed 1 day after the trade
2024-07-24Mellion Michelle LofficerSale201 @ $18.01$4K−100.0% of holding−47.5%−102.0%0Form 4 · filed 2 days after the trade
2024-07-18Mellion Michelle LofficerSale12,625 @ $18.20$230K−100.0% of holding−43.5%−95.0%0Form 4 · filed 1 day after the trade
2024-07-16Mellion Michelle LofficerSale5,901 @ $18.00$106K−100.0% of holding−50.0%−91.2%0Form 4 · filed same day
2024-07-12Mellion Michelle LofficerSale3,288 @ $18.04$59K−100.0% of holding−44.0%−87.9%0Form 4 · filed 4 days after the trade
2024-07-02Mellion Michelle LofficerSale37 @ $18.07$669−100.0% of holding−37.2%−84.2%0Form 4 · filed 1 day after the trade
2024-07-01Mellion Michelle LofficerSale875 @ $18.01$16K−100.0% of holding−37.2%−87.2%0Form 4 · filed 2 days after the trade
2024-06-24Mellion Michelle LofficerSale9,260 @ $18.19$168K−100.0% of holding−1.3%−89.3%0Form 4 · filed 2 days after the trade
2024-06-12Mellion Michelle LofficerSale1,086 @ $18.06$20K−100.0% of holding−10.7%−83.3%0Form 4 · filed 1 day after the trade
2024-06-11Mellion Michelle LofficerSale500 @ $18.04$9K−100.0% of holding−10.7%−84.2%0Form 4 · filed 2 days after the trade
2024-06-06Mellion Michelle LofficerSale1,411 @ $18.00$25K−100.0% of holding−4.6%−81.7%0Form 4 · filed 1 day after the trade
2024-06-05Mellion Michelle LofficerSale7,245 @ $18.09$131K−100.0% of holding−11.7%−81.2%0Form 4 · filed 2 days after the trade
2024-05-17Svenstrup NielsofficerSale10,000 @ $13.41$134K−100.0% of holding+20.7%−80.0%0Form 4 · filed same day

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

97 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-18KEATING LAURIEdirectorAward / grant34,00034,000Form 4
2026-06-18RA CAPITAL MANAGEMENT, L.P.directorAward / grant34,00034,000Form 4
2026-06-18Mayer HowarddirectorAward / grant34,00034,000Form 4
2026-06-18Resnick JoshuadirectorAward / grant34,00034,000Form 4
2026-06-18Wyman LisadirectorAward / grant34,00034,000Form 4
2026-06-18Dable Habib JdirectorAward / grant34,00034,000Form 4
2026-06-18Finer Mitchell H.directorAward / grant34,00034,000Form 4
2026-06-18HENSON HEIDIdirectorAward / grant34,00034,000Form 4
2026-03-01Vittiglio JosephofficerAward / grant30,71765,717Form 4
2026-03-01McArthur James GdirectorAward / grant731,250731,250Form 4
2026-03-01Vittiglio JosephofficerAward / grant120,000120,000Form 4
2026-03-01Donnelly NoelofficerAward / grant76,793113,687Form 4
2026-03-01Donnelly NoelofficerAward / grant300,000300,000Form 4
2026-03-01STRECK PAULofficerAward / grant50,30078,105Form 4
2026-03-01STRECK PAULofficerAward / grant196,500196,500Form 4
2026-03-01Kasraian KasraofficerAward / grant34,55751,307Form 4
2026-03-01Kasraian KasraofficerAward / grant135,000135,000Form 4
2026-03-01McArthur James GdirectorAward / grant187,688301,601Form 4
2025-12-08Vittiglio JosephofficerAward / grant160,000160,000Form 4
2025-12-08Vittiglio JosephofficerAward / grant35,00035,000Form 4
2025-11-04Donnelly NoelofficerAward / grant203,339203,339Form 4
2025-11-04McArthur James GdirectorDisposition352,7050Form 4
2025-11-04McArthur James GdirectorAward / grant352,705352,705Form 4
2025-11-04McArthur James GdirectorDisposition40,8150Form 4
2025-11-04McArthur James GdirectorAward / grant40,81540,815Form 4
2025-11-04McArthur James GdirectorDisposition466,0950Form 4
2025-11-04McArthur James GdirectorAward / grant466,095466,095Form 4
2025-11-04McArthur James GdirectorDisposition275,0000Form 4
2025-11-04McArthur James GdirectorAward / grant275,000275,000Form 4
2025-11-04McArthur James GdirectorDisposition300,0000Form 4
2025-11-04McArthur James GdirectorAward / grant300,000300,000Form 4
2025-11-04Donnelly NoelofficerDisposition203,3390Form 4
2025-11-04Donnelly NoelofficerDisposition169,0370Form 4
2025-11-04Donnelly NoelofficerAward / grant169,037169,037Form 4
2025-11-04Donnelly NoelofficerDisposition144,0000Form 4
2025-11-04Donnelly NoelofficerAward / grant144,000144,000Form 4
2025-11-04STRECK PAULofficerDisposition202,81640,000Form 4
2025-11-04STRECK PAULofficerAward / grant202,816202,816Form 4
2025-11-04STRECK PAULofficerDisposition40,0000Form 4
2025-11-04STRECK PAULofficerAward / grant40,000242,816Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.